α-Synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of parkinson disease

Journal of Neuropathology and Experimental Neurology

Volumn 68, Issue 5, 2009, Pages 515-524

  McFarland, Nikolaus R ^a,c   Fan, Zhanyun ^a   Xu, Kui ^a   Schwarzschild, Michael A ^a   Feany, Mel B ^b   Hyman, Bradley T ^a   McLean, Pamela J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Bldg 114 ^*  (United States)

Author keywords

Adeno associated virus; Dopamine; Lewy bodies; Striatum; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

ADENOVIRUS VECTOR; ALANINE; ALPHA SYNUCLEIN; ALPHA SYNUCLEIN S129; ASPARTIC ACID; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; DOPAMINE; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; NERVE PROTEIN; SERINE;

ADENO ASSOCIATED VIRUS; AMINO ACID SUBSTITUTION; ANIMAL MODEL; ARTICLE; CELL DENSITY; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; INJECTION; MUTANT; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; SUBSTANTIA NIGRA; VIRUS RECOMBINANT; WILD TYPE; ANIMAL; BASAL GANGLION; CELL COUNT; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ALANINE; ALPHA-SYNUCLEIN; ANIMALS; ASPARTIC ACID; BASAL GANGLIA; CELL COUNT; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOPAMINE; GREEN FLUORESCENT PROTEINS; HUMANS; MUTATION; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SERINE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 70149118325     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181a24b53     Document Type: Article

References (52)

1. Baba M, Nakajo S, Tu PH, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998;152:879-884
2. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840
3. Tu PH, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 1998;44:415-422
4. Iwai A, Masliah E, Yoshimoto M, et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995;14:467-475
5. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18: 106-108
6. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047
7. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004;55:153-156
8. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004;364:1167-1169
9. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003;302:841
10. Wood-Kaczmar A, Gandhi S, Wood NW. Understanding the molecular causes of Parkinson's disease. Trends Mol Med 2006;12:521-528
11. Kotzbauer PT, Giasson BI, Kravitz AV, et al. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol 2004;187:279-288
12. Feany MB. New genetic insights into Parkinson's disease. N Engl J Med 2004;351:1937-1940
13. Conway KA, Harper JD, Lansbury PT Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000;39:2552-2563
14. Hashimoto M, Hsu LJ, Sisk A, et al. Human recombinant NACP/alphasynuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease. Brain Res 1998;799:301-306
15. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998;4:1318.
16. Greenbaum EA, Graves CL, Mishizen-Eberz AJ, et al. The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem 2005;280:7800.
17. Conway KA, Lee SJ, Rochet JC, et al. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann NY Acad Sci 2000;920:42-45
18. Miller DW, Hague SM, Clarimon J, et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004;62:1835-1838
19. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000;404:394-398
20. Chesselet MF. In vivo alpha-synuclein overexpression in rodents: A useful model of Parkinson's disease? Exp Neurol 2008;209:22-27
21. Springer W, Kahle PJ. Mechanisms and models of alpha-synucleinY related neurodegeneration. Curr Neurol Neurosci Rep 2006;6:432-436
22. Okochi M, Walter J, Koyama A, et al. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem 2000; 275:390-397
23. Ellis CE, Schwartzberg PL, Grider TL, et al. Alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J Biol Chem 2001;276:3879-3884
24. Fujiwara H, Hasegawa M, Dohmae N, et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160-164
25. Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006;281: 29739-29752
26. Saito Y, Kawashima A, Ruberu NN, et al. Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 2003;62:644-654
27. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005;8:657-663
28. Gorbatyuk OS, Li S, Sullivan LF, et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 2008;105:763-768
29. Kirik D, Rosenblad C, Burger C, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 2002;22:2780-2791
30. Lo Bianco C, Ridet JL, Schneider BL, et al. Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A 2002;99:10813-10818
31. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005;5:285-297
32. Howard DB, Powers K, Wang Y, et al. Tropism and toxicity of adeno-associated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia in vitro. Virology 2008;372:24-34
33. Taymans JM, Vandenberghe LH, Haute CV, et al. Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther 2007;18:195-206
34. St Martin JL, Klucken J, Outeiro TF, et al. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem 2007;100:1449-1457
35. West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991;231: 482-497
36. Broekman ML, Comer LA, Hyman BT, et al. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 2006;138:501-510
37. Klein RL, Dayton RD, Leidenheimer NJ, et al. Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther 2006;13:517-527
38. Reimsnider S, Manfredsson FP, Muzyczka N, et al. Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther 2007;15: 1504-1511
39. Maurin Y, Banrezes B, Menetrey A, et al. Three-dimensional distribution of nigrostriatal neurons in the rat: Relation to the topography of striatonigral projections. Neuroscience 1999;91:891-909
40. Schmidt N, Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 2001;108:1263-1282
41. Wersinger C, Prou D, Vernier P, et al. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J 2003;17: 2151-2153
42. Burger C, Gorbatyuk OS, Velardo MJ, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004;10:302-317
43. Paleologou KE, Schmid AW, Rospigliosi CC, et al. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem 2008;283:16895-16905
44. Cookson MR. The biochemistry of Parkinson's disease. Annu Rev Biochem 2005;74:29-52
45. Pronin AN, Morris AJ, Surguchov A, et al. Synucleins are a novel class of substrates for G proteinYcoupled receptor kinases. J Biol Chem 2000; 275:26515-26522
46. Arawaka S, Wada M, Goto S, et al. The role of G-proteinYcoupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. J Neurosci 2006;26:9227-9238
47. Wakamatsu M, Ishii A, Ukai Y, et al. Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J Neurosci Res 2007;85:1819-1825
48. Pronin AN, Carman CV, Benovic JL. Structure-function analysis of G protein-coupled receptor kinase-5. Role of the carboxyl terminus in kinase regulation. J Biol Chem 1998;273:31510-31518
49. Chuang TT, Paolucci L, De Blasi A. Inhibition of G proteinYcoupled receptor kinase subtypes by Ca2+/calmodulin. J Biol Chem 1996;271: 28691-28696
50. Cooper AA, Gitler AD, Cashikar A, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006;313:324-328
51. Parihar MS, Parihar A, Fujita M, et al. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci 2008;65: 1272-1284
52. Kontopoulos E, Parvin JD, Feany MB. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 2006;15:3012-23